Active, Not Recruiting
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation - CV185-543
Updated: 26 January, 2022 | ClinicalTrials.gov
Print Friendly Summary
Trial Details
Gender(s)
Age Range
Active, Not Recruiting
Treatment Options
Inclusion Criteria: 1. Had 1 or more pharmacy claim for apixaban or warfarin or dabigatran or rivaroxaban during the identification period (01-Jan-2013 to 30-Sep-2015). The first OAC pharmacy claim date during the identification period will be designated as the index date 2. Patients 18 years old or older as of the index date 3. At least 1 diagnosis of atrial fibrillation prior to or on index date, identified by any medical claim 4. At least 12 months of baseline period prior to index date with continuous enrollment Exclusion Criteria: 1. Evidence of valvular heart disease, transient atrial fibrillation, venous thromboembolism during the 12-month baseline period or on the index date 2. Evidence of pregnancy during the study period 3. Had a pharmacy claim for warfarin, apixaban, dabigatran, rivaroxaban, or edoxaban during the 12-month baseline period 4. Had more than 1 oral anticoagulant claim on the index date
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
